- Home
- PRZO vs CMMB Comparison
PRZO vs CMMB Comparison
Compare PRZO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- CMMB
- Stock Information
- Founded
- PRZO 2014
- CMMB 2004
- Country
- PRZO Israel
- CMMB Israel
- Employees
- PRZO N/A
- CMMB N/A
- Industry
- PRZO
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- CMMB Health Care
- Exchange
- PRZO Nasdaq
- CMMB Nasdaq
- Market Cap
- PRZO 20.1M
- CMMB 22.0M
- IPO Year
- PRZO 2023
- CMMB N/A
- Fundamental
- Price
- PRZO $1.32
- CMMB $3.09
- Analyst Decision
- PRZO
- CMMB Strong Buy
- Analyst Count
- PRZO 0
- CMMB 2
- Target Price
- PRZO N/A
- CMMB $26.50
- AVG Volume (30 Days)
- PRZO 602.0K
- CMMB 136.3K
- Earning Date
- PRZO 08-28-2025
- CMMB 08-14-2025
- Dividend Yield
- PRZO N/A
- CMMB N/A
- EPS Growth
- PRZO N/A
- CMMB N/A
- EPS
- PRZO N/A
- CMMB N/A
- Revenue
- PRZO $1,007,440.00
- CMMB N/A
- Revenue This Year
- PRZO N/A
- CMMB N/A
- Revenue Next Year
- PRZO N/A
- CMMB N/A
- P/E Ratio
- PRZO N/A
- CMMB N/A
- Revenue Growth
- PRZO 80.42
- CMMB N/A
- 52 Week Low
- PRZO $0.52
- CMMB $2.99
- 52 Week High
- PRZO $3.16
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- PRZO 41.16
- CMMB 24.58
- Support Level
- PRZO $1.35
- CMMB $2.99
- Resistance Level
- PRZO $1.43
- CMMB $3.86
- Average True Range (ATR)
- PRZO 0.09
- CMMB 0.26
- MACD
- PRZO -0.01
- CMMB -0.02
- Stochastic Oscillator
- PRZO 29.61
- CMMB 8.85
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.